Breaking News

Tweet TWEET

Commencement of Clinical Trials, Financial Results, Upcoming Earnings Releases, and Asset Acquisitions - Research Report on

    Commencement of Clinical Trials, Financial Results, Upcoming Earnings
     Releases, and Asset Acquisitions - Research Report on Questcor, Jazz
                      Pharmaceuticals, Ariad, and USANA

PR Newswire

NEW YORK, October 25, 2013

NEW YORK, October 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ),
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Oxygen Biotherapeutics, Inc.
(NASDAQ: OXBT), and USANA Health Sciences Inc. (NYSE: USNA). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report

On October 22, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that
it will commence a Phase 2 study to explore the efficacy and safety of H.P.
Acthar Gel (repository corticotropin injection) for Acute Respiratory Distress
Syndrome (ARDS). According to Questcor, the Investigational New Drug (IND)
application for the study has been reviewed by the U.S. Food and Drug
Administration (FDA) and is now active. The Company stated that the study seek
to enroll up to 210 patients in a 4-week randomized, placebo controlled trial
designed to explore the efficacy and safety of several dosing regimens of
Acthar in patients with moderate to severe ARDS. The Company added that the
primary objective of the study will be to determine if Acthar increases the
number of ventilator-free days during the 28-day treatment period. Dr. David
Young, Questcor's Chief Scientific Officer, stated, "While Acthar's exact
mechanism of action is unknown, based on our understanding from scientific
literature and nonclinical data, we believe Acthar may be beneficial in ARDS
patients via its potential anti-inflammatory and immune-modulatory properties
that could reduce lung inflammation and injury, making ARDS a compelling area
to investigate further." The Full Research Report on Questcor Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR]

--

Jazz Pharmaceuticals Plc Research Report

On October 22, 2013, Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) announced
that it will report its Q3 2013 financial results after the market close on
Tuesday, November 5, 2013. The Company informed that it will also hold a
conference call on the same day at 4:30 p.m. EST/9:30 p.m. GMT to discuss
quarterly results and to provide a business and financial update. The Company
stated that the live webcast of the call and its replay will be available on
its Investor Relations website. The Full Research Report on Jazz
Pharmaceuticals Plc - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/5fe3_JAZZ]

--

Ariad Pharmaceuticals Inc. Research Report

On October 22, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that it will
report its Q3 2013 financial results before the market open on Wednesday,
November 6, 2013. Ariad stated that following the result release, its
management will host a conference call at 8:30 a.m. ET to discuss the results
and to provide a general corporate update. The Company informed that
interested parties can access the live webcast of the call and its replay
through its Investor Relations website. The Full Research Report on Ariad
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/161c_ARIA]

--

Oxygen Biotherapeutics, Inc. Research Report

On October 21, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics)
announced that it has signed a Definitive Agreement to acquire certain assets
of Phyxius Pharma. According to the Company, Phyxius Pharma is focused on the
development and near-term commercialization of levosimendan to prevent and
treat cardiac surgery patients at risk for developing low cardiac output
syndrome (LCOS), a significant unmet medical need addressing an estimated $600
million market in the U.S. The Company informed that under the terms of the
agreement, it will acquire the exclusive rights to develop and commercialize
levosimendan in North America, as well as integrating three key Phyxius Pharma
executives into the Company's management team. Oxygen Biotherapeutics stated
that the transaction is valued at c.$4.8 million in stock as of October 18,
2013, based on Oxygen Biotherapeutics issuing an aggregate of approximately
3.4 million shares of its common stock and securities convertible into common
stock to Phyxius Pharma's stockholders in a private placement. The Full
Research Report on Oxygen Biotherapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5700_OXBT]

--

USANA Health Sciences Inc. Research Report

On October 22, 2013, USANA Health Sciences Inc. (USANA) released its Q3 2013
results with net sales reported at $173.7 million, representing a 5.2% YoY
increase. The Company's net earnings were $16.8 million or $1.16 per diluted
share in Q3 2013, compared to net earnings of $17.5 million or $1.18 per
diluted share in Q3 2012. Dave Wentz, CEO of USANA, said, "During the third
quarter, we implemented a number of strategic initiatives at our 2013
International Convention. These initiatives, which include price reductions
and enhancements to our Associate compensation plan, are intended to drive
long-term, sustainable customer growth for USANA." For full-year 2013, USANA
anticipates consolidated net sales to range between $705 million and $710
million, and EPS to be between $5.35 and $5.40. The Full Research Report on
USANA Health Sciences Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ee40_USNA]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.